ImmTOR immune tolerance platform
GPTKB entity
Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:application |
gptkb:gene_therapy
gptkb:biologic_therapy enzyme therapy |
| gptkbp:clinicalTrialPhase |
in clinical development
|
| gptkbp:developedBy |
gptkb:Selecta_Biosciences
|
| gptkbp:goal |
prevent formation of anti-drug antibodies
|
| gptkbp:mechanismOfAction |
modulates immune response
uses biodegradable nanoparticles encapsulating rapamycin |
| gptkbp:purpose |
induce immune tolerance
|
| gptkbp:target |
antigen-specific T cells
|
| gptkbp:usedIn |
gptkb:SEL-212
collaborations with other biopharma companies |
| gptkbp:bfsParent |
gptkb:SEL-212
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
ImmTOR immune tolerance platform
|